Diagnosis of primary osseous malignant tumors with 18F-FDG PET/CT in patients over 40 years old

中华核医学与分子影像杂志 Pub Date : 2019-09-25 DOI:10.3760/CMA.J.ISSN.2095-2848.2019.09.002

P. Chen, Wei Chen, Xiaofeng Li

{"title":"Diagnosis of primary osseous malignant tumors with 18F-FDG PET/CT in patients over 40 years old","authors":"P. Chen, Wei Chen, Xiaofeng Li","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.002","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the value of 18F-fluorodeoxyglucose (FDG) PET/CT in the diagnosis of different pathological types of primary osseous malignant tumors (POMT) in patients over 40 years old. \n \n \nMethods \nFifty-two patients (30 males, 22 females, median age: 60(41-81)years) with POMT who underwent 18F-FDG PET/CT and were pathologically confirmed from January 2013 to May 2018 in Cancer Hospital of Tianjin Medical University were reviewed. The region of interest was drawn and the standardized uptake value (SUV) was automatically measured. The SUV in different pathological types of POMT was compared using one-way analysis of variance or two-sample t test. \n \n \nResults \nThe 52 POMT included 22 sarcomas, 16 isolated myelomas (IM), and 14 primary bone lymphomas (PBL). The SUV in PBL was significantly higher that than in sarcomas and IM with the maximum SUV (SUVmax) of 21.6±12.4, 13.5±7.7 and 9.0±6.4 respectively(F=7.56, P<0.01), and the mean SUV (SUVmean) of 12.9±7.8, 7.5±4.5, and 5.6±4.4, respectively(F=6.92, P<0.01). In the sarcoma group, the SUV of undifferentiated sarcomas was significantly higher than that of other well-differentiated sarcomas (SUVmax: 21.1±5.4 vs 11.3±6.9, SUVmean: 11.8±3.3 vs 6.3±4.1; t=-2.92, -2.71, both P<0.01). The growth pattern of sarcomas and IM was different on CT images. \n \n \nConclusions \nThe FDG uptake of PBL is higher than that of other pathological types. CT features are helpful for the differential diagnosis of POMT in 18F-FDG PET/CT. \n \n \nKey words: \nBone neoplasms; Middle aged; Aged; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"518-521"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华核医学与分子影像杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the value of 18F-fluorodeoxyglucose (FDG) PET/CT in the diagnosis of different pathological types of primary osseous malignant tumors (POMT) in patients over 40 years old. Methods Fifty-two patients (30 males, 22 females, median age: 60(41-81)years) with POMT who underwent 18F-FDG PET/CT and were pathologically confirmed from January 2013 to May 2018 in Cancer Hospital of Tianjin Medical University were reviewed. The region of interest was drawn and the standardized uptake value (SUV) was automatically measured. The SUV in different pathological types of POMT was compared using one-way analysis of variance or two-sample t test. Results The 52 POMT included 22 sarcomas, 16 isolated myelomas (IM), and 14 primary bone lymphomas (PBL). The SUV in PBL was significantly higher that than in sarcomas and IM with the maximum SUV (SUVmax) of 21.6±12.4, 13.5±7.7 and 9.0±6.4 respectively(F=7.56, P<0.01), and the mean SUV (SUVmean) of 12.9±7.8, 7.5±4.5, and 5.6±4.4, respectively(F=6.92, P<0.01). In the sarcoma group, the SUV of undifferentiated sarcomas was significantly higher than that of other well-differentiated sarcomas (SUVmax: 21.1±5.4 vs 11.3±6.9, SUVmean: 11.8±3.3 vs 6.3±4.1; t=-2.92, -2.71, both P<0.01). The growth pattern of sarcomas and IM was different on CT images. Conclusions The FDG uptake of PBL is higher than that of other pathological types. CT features are helpful for the differential diagnosis of POMT in 18F-FDG PET/CT. Key words: Bone neoplasms; Middle aged; Aged; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose

查看原文本刊更多论文

40岁以上原发性骨恶性肿瘤的18F-FDG PET/CT诊断

目的探讨18f -氟脱氧葡萄糖(FDG) PET/CT对40岁以上不同病理类型原发性骨恶性肿瘤(POMT)的诊断价值。方法回顾2013年1月至2018年5月天津医科大学肿瘤医院经18F-FDG PET/CT病理证实的52例POMT患者，其中男30例，女22例，中位年龄:60(41-81)岁。绘制感兴趣区域并自动测量标准化摄取值(SUV)。采用单因素方差分析或双样本t检验比较不同病理类型POMT的SUV。结果52例POMT包括22例肉瘤，16例分离性骨髓瘤(IM)， 14例原发性骨淋巴瘤(PBL)。PBL的SUV显著高于肉瘤和IM，最大SUV (SUVmax)分别为21.6±12.4、13.5±7.7和9.0±6.4 (F=7.56, P<0.01)，平均SUV (SUVmean)分别为12.9±7.8、7.5±4.5和5.6±4.4 (F=6.92, P<0.01)。在肉瘤组中，未分化肉瘤的SUV明显高于其他高分化肉瘤(SUVmax: 21.1±5.4 vs 11.3±6.9,SUVmean: 11.8±3.3 vs 6.3±4.1;t=-2.92， -2.71, P均<0.01)。肉瘤和IM在CT上的生长模式不同。结论PBL的FDG摄取高于其他病理类型。CT表现有助于18F-FDG PET/CT对POMT的鉴别诊断。关键词:骨肿瘤;中年;岁的;正电子发射断层扫描;断层扫描，x射线计算机;脱氧葡萄糖

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华核医学与分子影像杂志核医学，分子影像

自引率

0.00%

发文量

5088

期刊介绍： Chinese Journal of Nuclear Medicine and Molecular Imaging (CJNMMI) was established in 1981, with the name of Chinese Journal of Nuclear Medicine, and renamed in 2012. As the specialized periodical in the domain of nuclear medicine in China, the aim of Chinese Journal of Nuclear Medicine and Molecular Imaging is to develop nuclear medicine sciences, push forward nuclear medicine education and basic construction, foster qualified personnel training and academic exchanges, and popularize related knowledge and raising public awareness. Topics of interest for Chinese Journal of Nuclear Medicine and Molecular Imaging include: -Research and commentary on nuclear medicine and molecular imaging with significant implications for disease diagnosis and treatment -Investigative studies of heart, brain imaging and tumor positioning -Perspectives and reviews on research topics that discuss the implications of findings from the basic science and clinical practice of nuclear medicine and molecular imaging - Nuclear medicine education and personnel training - Topics of interest for nuclear medicine and molecular imaging include subject coverage diseases such as cardiovascular diseases, cancer, Alzheimer’s disease, and Parkinson’s disease, and also radionuclide therapy, radiomics, molecular probes and related translational research.